{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:35:36Z","timestamp":1740144936826,"version":"3.37.3"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.1093\/jbmr\/zjae080","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:00:32Z","timestamp":1718197232000},"page":"631-632","source":"Crossref","is-referenced-by-count":0,"title":["A novel oral hPTH(1-34) unveils the promise of modeling-based anabolism with no increase in bone remodeling"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-788X","authenticated-orcid":false,"given":"Jacques P","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Medicine, Universit\u00e9 Laval , Quebec, Quebec G1V 0A6 , Canada"},{"name":"Infectious and Immune Diseases Axis, CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Centre , Quebec, Quebec G1V 4G2 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"2024072411363247900_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.09.002","article-title":"Current use of bone turnover markers in the management of osteoporosis","volume":"109\u2013110","author":"Brown","year":"2022 \u2013","journal-title":"Clin Biochem"},{"issue":"3","key":"2024072411363247900_ref2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00198-018-04819-1","article-title":"Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE","volume":"30","author":"Eastell","year":"2019","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024072411363247900_ref3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024072411363247900_ref4","doi-asserted-by":"crossref","first-page":"zjae057","DOI":"10.1093\/jbmr\/zjae057","article-title":"Oral daily PTH (1-34) tablets in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, six-month, phase 2 study","author":"Tripto-Shkolnik","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2024072411363247900_ref5","article-title":"An oral PTH(1-34) formulation with a pharmacokinetic profile optimized for the treatment of osteoporosis","volume":"33","author":"Burshtein","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024072411363247900_ref6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2024072411363247900_ref7","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s00198-019-05111-6","article-title":"Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study","volume":"30","author":"Sugimoto","year":"2019","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024072411363247900_ref8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4158\/EP161394.OR","article-title":"Anabolic bone window with weekly Teriparatide therapy in postmenopausal osteoporosis: a pilot study","volume":"23","author":"Gopalaswamy","year":"2017","journal-title":"Endocr Pract"},{"issue":"9","key":"2024072411363247900_ref9","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae080\/58201860\/zjae080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/6\/631\/58622106\/zjae080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/6\/631\/58622106\/zjae080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:32:58Z","timestamp":1721874778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/6\/631\/7691408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":9,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]},"published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae080","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"type":"print","value":"0884-0431"},{"type":"electronic","value":"1523-4681"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6,1]]}}}